These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

585 related items for PubMed ID: 26081917

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ, Chen JC, Cai Z, Chan C, Reilly RM.
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
    Chakraborty S, Sarma HD, Vimalnath KV, Pillai MR.
    Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.
    Johnson CV, Shelton T, Smith CJ, Ma L, Perry MC, Volkert WA, Hoffman TJ.
    Cancer Biother Radiopharm; 2006 Apr; 21(2):155-66. PubMed ID: 16706636
    [Abstract] [Full Text] [Related]

  • 11. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
    Blankenberg FG, Levashova Z, Goris MG, Hamby CV, Backer MV, Backer JM.
    J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
    [Abstract] [Full Text] [Related]

  • 12. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL, Hansen HJ, Goldenberg DM.
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [Abstract] [Full Text] [Related]

  • 13. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
    Müller C, Struthers H, Winiger C, Zhernosekov K, Schibli R.
    J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
    [Abstract] [Full Text] [Related]

  • 14. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
    Swärd C, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Stridsberg M, Forssell-Aronsson E, Nilsson O, Kölby L.
    Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
    [Abstract] [Full Text] [Related]

  • 15. Synthesis of radiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2 proto-oncogene.
    Gallazzi F, Wang Y, Jia F, Shenoy N, Landon LA, Hannink M, Lever SZ, Lewis MR.
    Bioconjug Chem; 2003 Feb; 14(6):1083-95. PubMed ID: 14624621
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
    Dalm SU, Nonnekens J, Doeswijk GN, de Blois E, van Gent DC, Konijnenberg MW, de Jong M.
    J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
    Persson M, Rasmussen P, Madsen J, Ploug M, Kjaer A.
    Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
    [Abstract] [Full Text] [Related]

  • 20. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
    Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, Provencher-Bolliger A, Reubi JC, Maecke HR.
    Cancer Res; 2011 Feb 01; 71(3):1009-18. PubMed ID: 21245097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.